KOSE:A011000 1 Year Share Price vs Fair ValueExplore GeneOne Life Science’s Fair Values from the Community and select yoursGeneOne Life Science (KRX:011000) Second Quarter 2025 ResultsKey Financial Results Revenue: ₩6.81b (down 27% from 2Q 2024). Net loss: ₩15.4b (loss widened by 20% from 2Q 2024). ₩187 loss per share (further deteriorated from ₩39.00 loss in 2Q 2024).
KOSE:A011000 Earnings and Revenue History August 20th 2025
All figures shown in the chart above are for the trailing 12 month (TTM) period
GeneOne Life Science shares are down 9.3% from a week ago.
Risk Analysis
Be aware that GeneOne Life Science is showing 3 warning signs in our investment analysis that you should know about…
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.